

Mystery of immunosuppressive drug's biosynthesis finally unlocked

June 21 2019, by Li Yuan



Compartmentalized biosynthesis of mycophenolic acid. Credit: ZHANG Wei and LI Shengying

Mycophenolic acid (MPA), discovered in 1893, was the first natural antibiotic to be isolated and crystallized in human history. Today, this fungal metabolite has been developed into multiple first-line immunosuppressive drugs to control immunologic rejection during organ transplantation and treat various autoimmune diseases.

However, the biogenesis of such an old and important molecule was an



unsolved mystery for more than a century.

Recently, scientists from the Qingdao Institute of Bioenergy and Bioprocess Technology (QIBEBT) of the Chinese Academy of Sciences cracked this intriguing <u>black box</u> by fully elucidating the biosynthetic pathway of MPA. The results were published in *Proceedings of the National Academy of Sciences* of the United States of America (*PNAS*).

The researchers revealed that MPA biogenesis requires very unique cooperation between biosynthetic enzymes and β -oxidation catabolic machinery.

Interestingly, the involved enzymes were observed to be compartmentalized in different organelles including cytoplasm, the endoplasmic reticulum, the Golgi apparatus, and peroxisomes.

In this pathway, the oxygenase MpaB', which is intriguingly homologous to a latex-clearing enzyme, was identified as the long-sought key <u>enzyme</u> responsible for oxidative cleavage of the farnesyl side chain that is structurally similar to rubber.

The resultant carboxylic acid intermediate allows it to be recognized by the fungal β -oxidation machinery located in the peroxisomes. The following successive β -oxidation chain-shortening process is elegantly gated by the peroxisomal acyl-CoA hydrolase MpaH', thus leading to efficient and specific production of MPA.

The scientists concluded that compartmentalized biosynthesis is likely a very important characteristic of natural product biosynthesis in higher organisms such as fungi and plants.

They hope their work will prompt more research on this phenomenon since there is only very limited knowledge about the subcellular



localization of fungal biosynthetic enzymes and their involvement in product formation and intermediate trafficking.

The researchers also hope the insights gained from this study will encourage industrial strain improvements that would lower the cost of this popular immunosuppressive drug as well as novel drug development based on MPA structural derivatization. "Ultimately, we wish that millions of patients will benefit from this <u>basic research</u>," said LI Shengying, corresponding author of the study.

More information: Wei Zhang et al, Compartmentalized biosynthesis of mycophenolic acid, *Proceedings of the National Academy of Sciences* (2019). DOI: 10.1073/pnas.1821932116

Provided by Chinese Academy of Sciences

Citation: Mystery of immunosuppressive drug's biosynthesis finally unlocked (2019, June 21) retrieved 2 May 2024 from <u>https://phys.org/news/2019-06-mystery-immunosuppressive-drug-biosynthesis.html</u>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.